

Wen-Xian Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3854844/publications.pdf>

Version: 2024-02-01

152
papers

2,348
citations

279701

23
h-index

360920

35
g-index

158
all docs

158
docs citations

158
times ranked

3071
citing authors

#	ARTICLE	IF	CITATIONS
1	Deep RNA Sequencing Revealed Fusion Junctional Heterogeneity May Predict Crizotinib Treatment Efficacy in ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 264-276.	0.5	15
2	Clinicopathological features and resistance mechanisms in <i>HIPI</i> - <i>ALK</i> -rearranged lung cancer: A multicenter study. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 177-186.	1.5	7
3	Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. <i>Clinical Cancer Research</i> , 2022, 28, 461-467.	3.2	24
4	The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1693-1703.	2.0	18
5	Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs). <i>Annals of Palliative Medicine</i> , 2022, 11, 1624-1634.	0.5	3
6	Pharmacist-Led Management Improves Treatment Adherence and Quality of Life in Opioid-Tolerant Patients With Cancer Pain: A Randomized Controlled Trial. <i>Pain and Therapy</i> , 2022, 11, 241-252.	1.5	1
7	Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. <i>BMC Medicine</i> , 2022, 20, 42.	2.3	26
8	Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements. <i>Npj Precision Oncology</i> , 2022, 6, 20.	2.3	7
9	Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: a multicenter retrospective study. <i>Genes Chromosomes and Cancer</i> , 2022, , .	1.5	3
10	Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients. <i>Clinical Imaging</i> , 2022, 86, 31-37.	0.8	0
11	Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial. <i>BMC Medicine</i> , 2022, 20, 154.	2.3	7
12	Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study. <i>BMC Pulmonary Medicine</i> , 2022, 22, 179.	0.8	5
13	Abstract CT527: A phase I open-label study of FGFR/VEGFR inhibitor FH-2001 in patients with advanced solid tumors. <i>Cancer Research</i> , 2022, 82, CT527-CT527.	0.4	0
14	First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1 ⁺ non-small cell lung cancer (NSCLC) or mesothelioma. <i>Journal of Clinical Oncology</i> , 2022, 40, 9071-9071.	0.8	5
15	DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues. <i>Journal of Clinical Oncology</i> , 2022, 40, 3079-3079.	0.8	1
16	The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-7.	0.4	3
17	The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 361-371.	3.3	30
18	Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database. <i>Open Medicine (Poland)</i> , 2021, 16, 169-174.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Baseline anemia and anemia grade are independent prognostic factors for stage IV non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2021, 14, 59.	0.4	10
20	Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis. <i>Cell Death and Disease</i> , 2021, 12, 106.	2.7	16
21	High-throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion. <i>Cancer Communications</i> , 2021, 41, 192-196.	3.7	3
22	EXT1 methylation promotes proliferation and migration and predicts the clinical outcome of non-small cell lung carcinoma via WNT signalling pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 2609-2620.	1.6	12
23	A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 815-825.	1.3	15
24	Noncanonical Gene Fusions Detected at the DNA Level Necessitate Orthogonal Diagnosis Methods Before Targeted Therapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 344-348.	0.5	6
25	Comparison of circulating tumor cell (CTC) detection rates with epithelial cell adhesion molecule (EpCAM) and cell surface vimentin (CSV) antibodies in different solid tumors: a retrospective study. <i>PeerJ</i> , 2021, 9, e10777.	0.9	15
26	Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study. <i>Lung Cancer</i> , 2021, 155, 20-27.	0.9	32
27	Distinct mutational backgrounds and clonal architectures implicated prognostic discrepancies in small-cell carcinomas of the esophagus and lung. <i>Cell Death and Disease</i> , 2021, 12, 472.	2.7	0
28	Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 657283.	1.3	10
29	Chinese advanced fusion-dependent lung cancer patients: Molecular spectrum and treatment options using next generation sequencing—A multicenter study (Yangtze River Delta Lung Cancer Cooperation) <i>TJ</i> 10.7843.04 rgBT	1.3	10
30	Machine learning applied to near-infrared spectra for clinical pleural effusion classification. <i>Scientific Reports</i> , 2021, 11, 9411.	1.6	8
31	Liquid chromatography-mass spectrometry based metabolic characterization of pleural effusion in patients with acquired EGFR-TKI resistance. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 202, 114147.	1.4	2
32	Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 6309-6317.	0.9	7
33	Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial. <i>BMC Cancer</i> , 2021, 21, 1033.	1.1	9
34	A real-world study in advanced non-small cell lung cancer with de novo brain metastasis. <i>Journal of Cancer</i> , 2021, 12, 1467-1473.	1.2	1
35	A standard for hilar and intrapulmonary lymph node dissection and pathological examination in early non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 4587-4599.	1.3	5
36	High accuracy detection of malignant pleural effusion based on label-free surface-enhanced Raman spectroscopy and multivariate statistical analysis. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2020, 226, 117632.	2.0	16

#	ARTICLE	IF	CITATIONS
37	Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multicenter study. <i>Cancer Medicine</i> , 2020, 9, 12-18.	1.3	10
38	Metabolic and lipidomic characterization of malignant pleural effusion in human lung cancer. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 180, 113069.	1.4	26
39	Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 556-567.	0.5	66
40	A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations. <i>Translational Oncology</i> , 2020, 13, 329-335.	1.7	24
41	Simultaneous Detection of Gene Fusions and Base Mutations in Cancer Tissue Biopsies by Sequencing Dual Nucleic Acid Templates in Unified Reaction. <i>Clinical Chemistry</i> , 2020, 66, 178-187.	1.5	20
42	Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 572853.	1.3	15
43	Evaluating the Potential of T Cell Receptor Repertoires in Predicting the Prognosis of Resectable Non-Small Cell Lung Cancers. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 73-83.	1.8	24
44	Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. <i>Translational Lung Cancer Research</i> , 2020, 9, 1853-1861.	1.3	18
45	PD-L1 expression level in different thymoma stages and thymic carcinoma: a meta-analysis. <i>Tumori</i> , 2020, 106, 306-311.	0.6	10
46	Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer. <i>Translational Oncology</i> , 2020, 13, 100784.	1.7	13
47	A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib. <i>Frontiers in Oncology</i> , 2020, 10, 867.	1.3	8
48	A prostate cancer patient with isolated lung metastases: a case report. <i>Translational Cancer Research</i> , 2020, 9, 2064-2068.	0.4	8
49	PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 1385-1392.	0.6	12
50	Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial. <i>Oncologist</i> , 2020, 25, e1640-e1649.	1.9	10
51	Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs. <i>Translational Oncology</i> , 2020, 13, 100791.	1.7	17
52	Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 146, 224-229.	0.9	9
53	A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib. <i>Lung Cancer</i> , 2020, 142, 59-62.	0.9	18
54	Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study. <i>Clinical Lung Cancer</i> , 2020, 21, e349-e354.	1.1	23

#	ARTICLE	IF	CITATIONS
55	Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multicenter study. <i>Cancer Science</i> , 2020, 111, 679-686.	1.7	15
56	Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 3649-3661.	3.2	77
57	Large-scale targeted metabolomics method for metabolite profiling of human samples. <i>Analytica Chimica Acta</i> , 2020, 1125, 144-151.	2.6	48
58	MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study. <i>Translational Oncology</i> , 2020, 13, 100868.	1.7	14
59	Eye metastasis in lung adenocarcinoma mimicking anterior scleritis: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 410-414.	0.3	6
60	Treatment and prognosis of primary malignant melanoma of the esophagus. <i>Translational Cancer Research</i> , 2020, 9, 4141-4147.	0.4	4
61	Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non-small cell lung cancer patients: a multicenter retrospective study. <i>Translational Cancer Research</i> , 2020, 9, 6039-6049.	0.4	1
62	ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib. <i>BMC Cancer</i> , 2019, 19, 769.	1.1	23
63	Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients. <i>Lung Cancer</i> , 2019, 136, 23-29.	0.9	15
64	Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing. <i>Journal of Thoracic Oncology</i> , 2019, 14, e181-e183.	0.5	12
65	Fas signaling-mediated TH9 cell differentiation favors bowel inflammation and antitumor functions. <i>Nature Communications</i> , 2019, 10, 2924.	5.8	34
66	The efficacy and safety of anlotinib treatment for advanced lung cancer. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6549-6554.	1.0	24
67	Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients. <i>Journal of Thoracic Disease</i> , 2019, 11, 3712-3720.	0.6	3
68	Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. <i>Cancer Science</i> , 2019, 110, 3382-3390.	1.7	26
69	Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2019, 8, 392-400.	1.3	24
70	A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib. <i>Clinical Lung Cancer</i> , 2019, 20, e224-e228.	1.1	11
71	Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1-positive non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 3466-3474.	0.8	11
72	Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study. <i>Journal of Translational Medicine</i> , 2019, 17, 52.	1.8	27

#	ARTICLE	IF	CITATIONS
73	Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019, 14, e217-e219.	0.5	12
74	<p>FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9303-9307.	1.0	10
75	Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma. <i>Chinese Medical Journal</i> , 2019, 132, 3015-3017.	0.9	4
76	De Novo MET Amplification in Chinese Patients With Non-“Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study. <i>Clinical Lung Cancer</i> , 2019, 20, e171-e176.	1.1	22
77	The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2019, 20, e73-e76.	1.1	16
78	Genomic alterations and survival in young patients aged under 40 years with completely resected non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 140-140.	0.7	14
79	Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib. <i>Translational Cancer Research</i> , 2019, 8, 1630-1634.	0.4	0
80	Effect of icotinib on advanced lung adenocarcinoma patients with sensitive EGFR mutation detected in ctDNA by ddPCR. <i>Translational Cancer Research</i> , 2019, 8, 2858-2863.	0.4	5
81	Ginsenoside compound K inhibits growth of lung cancer cells via HIF-1 α -mediated glucose metabolism. <i>Cellular and Molecular Biology</i> , 2019, 65, 48-52.	0.3	7
82	Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2018, 118, 57-61.	0.9	39
83	EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report. <i>Lung Cancer</i> , 2018, 115, 131-134.	0.9	22
84	Dual drive coexistence of <i>EML4</i>-<i>ALK</i> and <i>TPM3</i>-<i>ROS1</i> fusion in advanced lung adenocarcinoma. <i>Thoracic Cancer</i> , 2018, 9, 324-327.	0.8	12
85	Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib. <i>Journal of Translational Medicine</i> , 2018, 16, 93.	1.8	10
86	Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib. <i>Lung Cancer</i> , 2018, 121, 101-104.	0.9	2
87	<sc><i>CEP72</i>-<i>ROS1</i></sc>: <sc>A</sc> novel <sc><i>ROS1</i></sc> oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing. <i>Thoracic Cancer</i> , 2018, 9, 652-655.	0.8	17
88	Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: <sc>A</sc> case report and literature review. <i>Thoracic Cancer</i> , 2018, 9, 159-163.	0.8	23
89	Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib. <i>Journal of Thoracic Disease</i> , 2018, 10, E359-E363.	0.6	14
90	TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib. <i>Journal of Thoracic Disease</i> , 2018, 10, 2991-2998.	0.6	31

#	ARTICLE	IF	CITATIONS
91	The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 2948-2959.	0.6	2
92	Efficacy and Safety of High-Dose Controlled-Release Oxycodone in the Treatment of Moderate to Severe Pain in Patients with Advanced Cancer: A Retrospective Study. <i>Medical Science Monitor</i> , 2018, 24, 0-0.	0.5	1
93	Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer. <i>Medicine (United States)</i> , 2018, 97, e12331.	0.4	12
94	Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7821-7825.	1.0	3
95	MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e202-e204.	0.5	26
96	Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated NSCLC patients who develop brain metastasis. <i>Archives of Medical Science</i> , 2018, 14, 1298-1307.	0.4	28
97	TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma. <i>EBioMedicine</i> , 2018, 32, 119-124.	2.7	61
98	Clonally related primary ALK rearranged adenocarcinoma and associated metastatic lesions. <i>Thoracic Cancer</i> , 2018, 9, 881-884.	0.8	3
99	A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib. <i>Cancer Biology and Therapy</i> , 2018, 19, 1097-1101.	1.5	6
100	MET amplification and activating mutation analysis in solid tumors using comprehensive NGS panel.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24267-e24267.	0.8	1
101	Mutation profiling of FGFR genes in solid tumors using comprehensive NGS panel.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24241-e24241.	0.8	1
102	Mutation profiling of TSC1 and TSC2 genes in solid tumors using comprehensive NGS panel.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24244-e24244.	0.8	2
103	The correlation between Crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21167-e21167.	0.8	0
104	Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>Medical Science Monitor</i> , 2018, 24, 8207-8212.	0.5	0
105	Association between BIM polymorphism and lung cancer outcomes: a meta-analysis. <i>Cellular and Molecular Biology</i> , 2018, 64, 92-96.	0.3	1
106	A meta-analysis of association between serum iron levels and lung cancer risk. <i>Cellular and Molecular Biology</i> , 2018, 64, 33-37.	0.3	4
107	Combined detection of CEA and CA125 for the diagnosis for lung cancer: A meta-analysis. <i>Cellular and Molecular Biology</i> , 2018, 64, 67-70.	0.3	7
108	Comparison of the MET gene amplification between primary tumor and metastatic lymph nodes in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2017, 8, 417-422.	0.8	20

#	ARTICLE	IF	CITATIONS
109	P3.02a-003 ALK and ROS1 Rearrangements, Coexistence and Treatment in EGFR-Wild Type Lung Adenocarcinoma - A Multicenter Study of 732 Cases. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1160-S1161.	0.5	4
110	A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with Acquired EGFR TKI resistance. <i>Cancer Medicine</i> , 2017, 6, 154-162.	1.3	82
111	Molecular Profiling and Survival of Completely Resected Primary Pulmonary Neuroendocrine Carcinoma. <i>Clinical Lung Cancer</i> , 2017, 18, e197-e201.	1.1	28
112	Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review. <i>Thoracic Cancer</i> , 2017, 8, 714-719.	0.8	8
113	Hemangioma of the rib: a rare case report and literature review. <i>Open Medicine (Poland)</i> , 2017, 12, 257-260.	0.6	3
114	MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations. <i>Clinical Lung Cancer</i> , 2017, 18, 213-219.e2.	1.1	13
115	Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. <i>Cancer Biology and Therapy</i> , 2017, 18, 883-887.	1.5	14
116	Salvage treatment with apatinib for advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1821-1825.	1.0	59
117	Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3187-3192.	1.0	25
118	Parallel VENTANA IHC and RT-PCR of ALK status in non-small cell lung cancer and response to crizotinib. <i>Journal of Clinical Oncology</i> , 2017, 35, 11623-11623.	0.8	1
119	Mutational profiling of Chinese ROS1 positive non-small cell lung cancer patients with required resistant to crizotinib by next generation sequencing. <i>Journal of Clinical Oncology</i> , 2017, 35, e13120-e13120.	0.8	1
120	Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations. <i>Journal of Clinical Oncology</i> , 2017, 35, e14050-e14050.	0.8	3
121	Comparison of the c-MET gene amplification between primary tumor and metastatic lymph nodes in non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, e23138-e23138.	0.8	1
122	Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer. <i>Archives of Medical Science</i> , 2016, 1, 107-111.	0.4	5
123	Efficacy of pemetrexed-based regimen in relapsed advanced thymic epithelial tumors and its association with thymidylate synthase level. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4527-4531.	1.0	5
124	Rare frequency of gene variation and survival analysis in thymic epithelial tumors. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6337-6342.	1.0	9
125	Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor. <i>OncoTargets and Therapy</i> , 2016, 9, 211.	1.0	7
126	Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma. <i>Cancer Medicine</i> , 2016, 5, 2694-2700.	1.3	26

#	ARTICLE	IF	CITATIONS
127	Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. <i>Lung Cancer</i> , 2016, 99, 166-171.	0.9	49
128	Response to crizotinib in a squamous cell lung carcinoma patient harbouring echinoderm microtubule-associated protein-like 4 anaplastic lymphoma translocation: A case report. <i>Thoracic Cancer</i> , 2016, 7, 355-357.	0.8	13
129	Patients with <i>ROS1</i> rearrangement-positive non-small cell lung cancer benefit from pemetrexed-based chemotherapy. <i>Cancer Medicine</i> , 2016, 5, 2688-2693.	1.3	35
130	Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma. <i>Lung Cancer</i> , 2016, 101, 16-21.	0.9	32
131	Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. <i>Journal of Translational Medicine</i> , 2016, 14, 188.	1.8	72
132	<i>HER2</i> mutations in Chinese patients with non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 78152-78158.	0.8	22
133	Chemotherapy and prognosis in advanced thymic carcinoma patients. <i>Clinics</i> , 2015, 70, 775-780.	0.6	16
134	Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer. <i>Archives of Medical Science</i> , 2015, 1, 164-168.	0.4	13
135	Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 1875.	1.0	14
136	Primary neuroendocrine tumors of the thymus: Clinical review of 22 cases. <i>Oncology Letters</i> , 2014, 8, 2125-2129.	0.8	10
137	Everolimus and zoledronic acid—a potential synergistic treatment for lung adenocarcinoma bone metastasis. <i>Acta Biochimica Et Biophysica Sinica</i> , 2014, 46, 792-801.	0.9	12
138	Brain Metastases from Esophageal Cancer: Clinical Review of 26 Cases. <i>World Neurosurgery</i> , 2014, 81, 131-135.	0.7	46
139	Adjuvant therapy in stage II thymic carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 349-352.	1.2	7
140	Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 591-595.	0.8	21
141	Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases. <i>Medical Oncology</i> , 2014, 31, 898.	1.2	9
142	Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis. <i>Journal of Thoracic Oncology</i> , 2014, 9, e67-e69.	0.5	11
143	Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer. <i>Oncology Letters</i> , 2014, 8, 351-354.	0.8	12
144	Retreatment with pemetrexed chemotherapy in advanced non-small cell lung cancer patient. <i>Journal of Thoracic Disease</i> , 2014, 6, 856-60.	0.6	4

#	ARTICLE	IF	CITATIONS
145	Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma. <i>Journal of Thoracic Disease</i> , 2014, 6, 1808-12.	0.6	6
146	Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy. <i>Chinese Medical Journal</i> , 2014, 127, 266-71.	0.9	7
147	Primary tracheobronchial mucoepidermoid carcinoma - a retrospective study of 32 patients. <i>World Journal of Surgical Oncology</i> , 2013, 11, 62.	0.8	26
148	Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. <i>Medical Oncology</i> , 2013, 30, 645.	1.2	64
149	Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib. <i>Molecular and Clinical Oncology</i> , 2013, 1, 875-878.	0.4	4
150	Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2013, 5, 400-5.	0.6	16
151	Cutaneous metastasis as a initial presentation in advanced non-small cell lung cancer and its poor survival prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1613-1617.	1.2	38
152	Analysis of the tumor length and other prognosis factors in pT1-2 node-negative esophageal squamous cell carcinoma in a Chinese population. <i>World Journal of Surgical Oncology</i> , 2012, 10, 273.	0.8	17